

Accepted Manuscript

The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma

Xiaoqing Zhu, Jiali Yang, Yanfeng Gao, Chunjing Wu, Lili Yi, Guodong Li, Yuanming Qi



PII: S0304-3835(17)30688-2

DOI: [10.1016/j.canlet.2017.10.043](https://doi.org/10.1016/j.canlet.2017.10.043)

Reference: CAN 13586

To appear in: *Cancer Letters*

Received Date: 23 July 2017

Revised Date: 25 October 2017

Accepted Date: 27 October 2017

Please cite this article as: X. Zhu, J. Yang, Y. Gao, C. Wu, L. Yi, G. Li, Y. Qi, The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma, *Cancer Letters* (2017), doi: 10.1016/j.canlet.2017.10.043.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma

Xiaoqing Zhu¹, Jiali Yang¹, Yanfeng Gao¹, Chunjing Wu¹, Lili Yi¹, Guodong Li^{1,2,*} and Yuanming Qi^{1,2,*}

¹*School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China*

²*Collaborative Innovation Center of New Drug Research and Safety Evaluation ,
Henan Province, China*

*Corresponding author: Prof. Guodong Li, Prof. Yuanming Qi

School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou
450001, China

Tel.: +86-371-67739620; fax: +86-371-67783235.

E-mail addresses: ligd@zzu.edu.cn (G. Li); qym@zzu.edu.cn (Y. Qi)

Abstract :

Inhibition of the VEGF/VEGF receptor (VEGFR) and angiopoietin-2 (Ang-2)/TEK receptor tyrosine kinase (Tie-2) pathway is a potential target for tumor angiogenesis. We previously showed that a peptide AS16 which dually inhibits VEGFR/Ang-2 could reduce the tumor growth and decrease the number of microvessels in tumor. However, its short circulating half-life in the serum limits its clinical applications. In this study, as an effort to prolong the short in vivo half-life of AS16, we designed a fusion protein containing peptide AS16 and an IgG Fc fragment. Pharmacokinetic study also revealed that AS16-Fc has a prolonged circulating half-life of about 231 minutes in rats. We examined the effects of treatment on the tumor vasculature and immune cell populations, tumor growth, in both the MCA-205 and S180 tumor models. We found that AS16-Fc dramatically reduced tumor volume, vascular density and tumor-associated macrophages. Macrophages were identified as potential novel targets following anti-angiogenic therapy, our findings imply a novel role for anti-angiogenic peptide AS16-Fc. These findings indicate that AS16-Fc could be more effective on inhibiting tumor growth angiogenesis and tumor immune microenvironment than that of peptide AS16.

Download English Version:

<https://daneshyari.com/en/article/8434862>

Download Persian Version:

<https://daneshyari.com/article/8434862>

[Daneshyari.com](https://daneshyari.com)